Quality of Life and Guidelines for PSA Screening
Menée sur des données issues de l'essai "European Randomized Study of Screening for Prostate Cancer", cette étude évalue, du point de vue du nombre d'années de vie ajustée par sa qualité, le bénéfice d'un dépistage du cancer de la prostate à l'aide du PSA
In this issue of the Journal, a study by Heijnsdijk et al.1 shows the way to a resolution of the long-standing controversy about screening for prostate cancer. This is welcome news, since the 2009 reports of the long-awaited European and North American randomized trials of prostate-specific antigen (PSA) screening did not settle the matter.2,3 In the American trial, screening did not reduce prostate-cancer mortality, but the results were confounded by frequent PSA screening in the control group (e.g., 52% in the sixth year).3 In the European Randomized Study of Screening for Prostate Cancer, the screening of men between the...
New England Journal of Medicine , éditorial, 2011